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Introduction
Migraine is a very complex condition; in fact its phys-
iopathology is not completely clear [1]. It is believed that
many neurotransmitters are implicated in this process [2],
and hormones have been shown to play a major role in
women [3]. Among the neuroendocrinological alterations,
disorders of the hypothalamic-hypophysial axis are
believed to be implicated in the pathogenesis of primary
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Abstract Many factors should be
considered when an episodic
migraine worsens and becomes
chronic. Prolactin (PRL) was linked
to the origin of pain in patients with
microprolactinomas who developed
different types of headaches. Our
team carried out studies on 27
patients with a background of
episodic headaches that became
chronic. The patients were evaluated
by means of a general examination, a
neurological examination and a hor-
monal profile. Of the 27 patients, 7
of them had an increased level of
prolactinaemia. All the patients were
women, ranging from 17 to 57 years
of age. Four of them had a pure form
of migraine without aura, whereas 3
patients had both migraines without
aura and tension-type headaches.
They suffered from headache for a
period ranging from 3 to 32 years
and their headache became chronic
4–12 months prior to the visit. Their
headache did not change in type, but
only in severity and frequency. Two
patients had no symptoms referable
to high PRL levels; 4 patients had
irregular menses or amenorrhoea.
One of these patients also suffered
galactorrhoea and two of these
patients had a microprolactinoma at
MRI; one patient was using estro-
progestinic drugs, so her menstrual
alteration could not be considered.
The patients were followed-up for a
period of 6–16 months. Six patients
responded favourably after being
treated with cabergoline, although
some had already tried other drugs,
which, however, had no effect on
their headache. One patient
improved after ceasing to take estro-
progestinic, in spite of increased lev-
els of PRL. Therefore, on this basis,
PRL levels should always be consid-
ered when headache worsens. It is an
adjunctive worsening factor, which
can be easily eliminated.
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headache syndromes. Premonitory symptoms in migraine
suggest a transient hypothalamic dysfunction, such as
polyuria, polydipsia, food craving and mood disturbances
[4, 5]. Some authors suggest a hypersensitivity of
dopamine receptors based on the observation that
migraineurs showed higher PRL after taking dopaminergic
agents [6–9]. Reduced responsiveness of pituitary lac-
totroph cells to the action of dopaminergic agents has also
been postulated [10]. In 1989, Awaki et al. [11] actually
suggested a serotoninergic hyperfunction rather than a
dopaminergic dysfunction. Until a few years ago, headache
related to pituitary tumours was thought to be due to the
mass effect of the tumour itself and to dural stretch [12,
13]. Levy et al. [14] reported how patients with microade-
nomas may suffer from severe disabling headache whilst
patients with large macroadenomas may not have headache
at all. This evidence shows that a tumour mass is not cor-
related to the presence or intensity of the headache, thus,
the cause of the headache lies in something other than the
volume of the tumour. The same concept was also consid-
ered by other authors who described the presence of
headache in patients with microprolactinoma [15, 16].
Referring to the type of headaches related to prolactino-
mas, the articles published up to now have cited cases of
trigeminal autonomic cephalalgias (TACs) [15], short last-
ing unilateral neuralgiform headache attacks with conjunc-
tival injection and tearing (SUNCT) [16, 17] and migraine
in only one case [17]. In reference to this single case of
migraine, the patient, a 40-year-old woman, had a previous
history of migraine many years before, until the age of 20.
When she was in her 40s, migraines appeared once again,
followed by amenorrhoea two months later, together with
an increased headache frequency, reaching up to two
attacks per week. She had high prolactin (PRL) levels due
to a microprolactinoma. When treated, firstly with
bromocriptine and later with cabergoline, she had a wors-
ening of headache, thus, both therapies were interrupted,
and migraine transformed into hemicrania continua [18].
Using only indomethacin solved the case. Moreover, both
cases suggest that PRL could have a direct role in initiat-
ing or worsening headache itself, considering that
headache and amenorrhoea were coincident [17].
Correlation between increased nocturnal levels of PRL
and cluster headache with nocturnal recrudescence has
been reported [19]. The study showed an altered regula-
tion of PRL secretion, both during active cluster periods
as well as during symptom-free intervals, rather than a
synchronising event between PRL secretion and pain, as
suggested by Polleri et al. [20].
There are only two articles containing data which seem-
ingly link migraine to hyperprolactinaemia, however, the
authors did not consider them related. According to the
study regarding geomagnetic earth activity, carried out by
Stoupel [21], an increase in magnetic activity corresponds
to an increase in PRL levels and a worsening of migraine.
The study carried out by Russian authors, dealing with the
application of phototherapy in children suffering from
headache [22], showed there was an increase in PRL levels
and a better mood, but no migraine variation. Many articles
report normal PRL values in migraineurs [8, 11]. However,
chronic migraines remain the main problem to deal with.
Determining what factors make migraines become chronic
is certainly not a simple task, nevertheless, in view of all
the above-mentioned elements, we can consider the possi-
bility that PRL could, to some extent, be responsible.
Patients and methods
Our team carried out a prospective observational open study in
order to evaluate whether PRL levels could be related to the
worsening of an episodic migraine. Our headache centre is a sec-
ond-level centre with neurologists expert in headache disorders;
patients reach the centre after undergoing a first-level check-up
carried out by neurologists. We recruited following unselected
patients who arrived for the first time to the headache centre, suf-
fering from chronic headache; their headaches had to have a fre-
quency of at least 15 days per month and had to have been chron-
ic for at least three months prior to the visit. They had to have a
background of episodic migraine without aura in line with the
current ICHD-II criteria [23]. The recruitment lasted one year.
The patients were then followed-up in the second-level service of
our hospital for headache disorders. Patients gave informed con-
sent for research. A neurologist of the headache centre, a special-
ist in internal medicine and a specialist in endocrinology visited
all of the patients. All the patients underwent the following tests:
magnetic resonance imaging (MRI) of the brain, electroen-
cephalography (EEG), X-ray scan of the neck, odontological
evaluation, general blood test, hormonal screening and PRL pro-
file. Other examinations were prescribed only in certain cases
when necessary. Serum PRL was tested with immunofluoromet-
ric assay (TOSOH Bioscience, Japan). PRL levels were measured
twice in a day during the same morning; we considered higher
than normal values in both samples as being pathological. A
blood test was repeated within 3 months. Values over 800 µIU/l
for women and over 400 µIU/l for men [24] can be referred to as
being abnormal. The blood samples were all taken in the same
laboratory. Each patient was followed-up for at least 6 months.
Therapy, consisting of 0.5 mg of cabergoline twice a week, was
suggested when a microadenoma or high serum PRL levels were
found. Cabergoline was considered effective in cases where
patients referred a minor number of days of headache per month.
Ethical approval




During a period of one year, we recruited 27 patients suf-
fering of chronic migraine: 1 man and 26 women, with
ages ranging from 17 to 71, and a mean age of 42; 17 of
them had a pure form of migraine, whereas 10 had both
migraine and tension-type headache. Headache character-
istics were similar throughout the whole group and in the
subgroup of patients with high PRL levels. They had
headaches for a period lasting from 3 to 50 years, with a
mean duration of 22 years. Their headaches became
chronic during the mean 1.3-year period before their first
visit (range, 3 months–10 years). All of the patients were
diagnosed as having chronic migraine, in line with the
current classification [23].
Each patient had at least one associated disease; 10
patients showed only 1 identified associated pathology,
whereas 17 patients showed more than one associated dis-
ease that may have been the cause of the worsening (refer
to data on the above-mentioned pathologies in Table 1).
Five patients abused analgesics, one of whom was in the
high PRL subgroup; we did not classify their headache as
overuse headache because they improved by simply cor-
recting their co-morbidity.
No major alterations in the blood tests were recorded,
except for PRL. FH and LSH were also measured, and were
within normal range. The value was higher only in post-
menopausal women, proportionally to their age; other
women of the same age had a normal PRL. Of the 27
patients, 7 had hyperprolactinaemia. The mean PRL serum
level was 597 (range 31–3300) for all the patients, and 2174
(range 1176–3300) in the seven patients with pathological
PRL values. After treatment, the PRL mean value in the
treated patients was 482 (range 10–1808). All of them were
women, their ages ranging from 17 to 57. Four patients had
a pure form of migraine without aura, whereas 3 patients
suffered from both migraine without aura and tension-type
headache. Their menses were regular prior to headache
worsening. As well as headache worsening, 2 patients had
irregular menses, two had amenorrhoea and one of these
Table 1 Characteristics of the patients recruited
General sample Sample with high PRL levels
Baseline After therapy (6–12 months)







Mean age, years (range) 42 (17–71) 27 (12–57)
Mean headache duration, years (range) 22 (3–50) 13 (2–10)
Mean duration of chronic headache, months (range) 15 (3–120) 9 (4–32)
Mean headache frequency, days per month (range) 23 (15–30) 20 (15–30) 2 (1–6)
Mean PRL levels (range) 597 (31–3300) 2174 (1176–3300) 482 (10–1808)
Presence of other associated diseasesa
Only one 10 –
More than one 27 –
No. patients with chronic use of drugs at entry 21 2 (oxcarbazepine; insulin for diabetes)
Therapy Main correcting 6 patients cabergoline 0.5 mg twice/week
co-morbidityb
1 patient stopped 
taking estroprog.
Abnormal pituitary MRI – Microadenoma (2 patients)
aThe principal, associated diseases were: allergy; psychiatric diseases; sleep disorders; muscle contractures of the face, head, cervical and
spine; autoimmune diseases; thyroid dysfunctions
b3 patients with tricyclic antidepressant, 2 patients, beta-blockers, 6 patients SSRI (of these 1 patient also beta-blockers), 4 patients ben-
zodiazepine. Of the whole group, 13 patients were also using drugs for other diseases they suffered from (sartane, ACE inhibitors, acetyl-
salicylic acid, antihistaminergic, beta-stimulators, alphalytics, steroids, atypical antipsychotics, drugs for thyroid dysfunctions)
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patients also had galactorrhoea. During headache worsen-
ing, only one patient was taking estroprogestinic drugs.
This patient showed menstrual irregularity after interrupt-
ing her hormonal therapy. The patients’ headache history
lasted from 3 to 32 years and their headaches became
chronic during the 4–12 months prior to the visit. They
were followed-up for a period ranging from 6 to 16 months.
Six patients with high PRL serum levels, suffering
from headache, were treated with 0.5 mg of cabergoline
twice a week, even if some had no other symptoms of
hyperprolactinaemia (amenorrhoea, galactorrhoea, etc).
Their headache improved within a few months and, once
again, became episodic. In only two cases (patients 5 and
6) headache changed characteristics and became a ten-
sion-type headache; these two patients had a micropro-
lactinoma at MRI. Their headache, a typical migraine
without aura, developed together with menarche, although
symptoms of hyperprolactinaemia developed only after a
number of years. The seventh patient simply stopped tak-
ing estroprogestinic; her headache improved despite her
PRL increasing to 1808; after ceasing to take estroproges-
tinic, her menses became irregular.
Table 2 Characteristics of the patients with high PRL serum levels
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7
Previous headache type MWAa MWA MWA MWA MWA MWA MWA
Headache type at entry MWAa MWA MWA MWA+T MWA+T MWA+T MWA
Headache type after therapy MWAa MWA MWA MWA T+MWA T MWA
Age, years 44a 57 38 41 17 22 22
Age of headache onset, years 14a 25 18 21 14 12 12
Duration of chronic headache, 4a 6 6 12 6 12 4
months
Mean headache frequency 30a 15 15 30 30 >15 15
at entry, days per month
Mean headache frequencyb 1a 6 <1 3c 1 <1 2
after therapy, days per month
Mean PRL levels at entry >3000a 1176 2914 2964 1200 2400 1266
Mean PRL levels after therapy, time 434a 300 474 270 <10 78 1808 
in months after commencing therapy (3 mts)a (3 mts) (5 mts) (3 mts) (12 mts) (12 mts) (12 mts)
Patients with chronic use of drugs, OXCa – – Insulin – – Estroprogest
entry
Other diseases –a (1) (2) (3) – (4) (5)
Microadenoma at MRI –a – – – 3 mm 4 mm –
Symptoms of high PRL Irregulara – – Irregular Amenorrhoea Amenorrhoea, Irregular 
(other than headache) mensesa menses galactorrhoea mensese
Therapy CBGa CBG CBG CBG CBG, CBG Estroprogest
relaxation dismission
Duration of follow-up (months) 6a 8 6 13 12 12+12 12d
All patients were women. MWA, migraine without aura; T, tension-type headache
aMenses related
bFrequency at time of PRL measuring control
cAfter 13 months headache frequency was one day per month
dHeadache worsened and galactorrhoea occurred four months after ceasing to take cabergoline, but the basal level of PRL was within nor-
mal levels. Again, after treatment with cabergoline both symptoms remitted. Tension-type headache with an important depressive syn-
drome appeared, and the patient did not show up for the follow-up after four months
OXC, oxcarbazepine; CBG, cabergoline; Relax, relaxation therapy
Other diseases: (1) at 29 years old hysterectomy for uterine myoma; (2) arterial hypertension normalised by therapy; (3) diabetes mellitus,
treated with insulin for many years and cystinuria; monolateral nephrectomy for giant kidney stone; history of irregular menses was attrib-
uted to important systemic dysfunction due to severe diabetes and cystinuria; (4) important depressive syndrome; (5) coagulant S protein
deficiency
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The general characteristics of the patients studied are
described in Table 1. In Table 2 the characteristics of the
seven patients with high PRL serum levels are shown.
Discussion
PRL was first measured in patients already suffering from
chronic headaches. We believe that a patient’s improve-
ment can be correlated to a decrease in PRL levels in
regards to the modification and time relation between
PRL serum level normalisation and headache severity
improvement during follow-up. Except for patient 7, the
only treatment given was 0.5 mg of cabergoline, twice a
week. Cabergoline was later used to experiment on three
other patients suffering from chronic migraine and psy-
chiatric comorbidity and who, because of their psychi-
atric pathology, had no pain relief after trying all the con-
ventional treatments. They showed no improvement, but
further studies need to be done. Referring to patient 7, we
interpreted her improvement as being the result of her no
longer taking estroprogestinic drugs. We cannot explain
why the patient, who experienced an increase in PRL, did
not worsen.
Two main central systems are believed to play an
important role in migraine pathogenesis. Some authors
have suggested hypersensitivity of dopamine receptors
based on the observation that migraineurs showed higher
PRL after taking dopaminergic agents [6–9]. Reduced
responsiveness of pituitary lactotroph cells to the effect
of dopaminergic agents has also been postulated on the
basis of a less marked inhibition of PRL secretion to L-
dopa in migraine [10]. It is difficult to explain our result,
or similar ones reported in the literature, by using this
hypothesis. In fact, we would expect patients treated with
cabergoline to worsen. We should also expect headache
worsening after PRL reduction. Awaki et al. [11] tested
pituitary function by means of a Triple Test (TRH, LH-
RH, insulin) in women suffering from migraine and a
group of controls consisting of healthy women, in order
to study simultaneously adeno-pituitary function. This
test produced an increase of PRL both in migraine and
controls, but the increase was significantly higher in
migraineurs. TSH also increased in both groups, but this
rise was less evident in patients (although not signifi-
cantly). These authors suggested a serotoninergic hyper-
function rather than a dopaminergic dysfunction, in fact
dopaminergic hypofunction can cause PRL hyper-
response, but it should also cause increased TSH secre-
tion, because dopamine inhibits TSH secretion. The
authors’ results cannot be explained by dopaminergic
hypofunction alone. Serotonin is known to increase PRL
secretion and decrease TSH secretion, therefore sero-
toninergic hyperfunction could explain the previous data.
Dopaminergic hypofunction could be the consequence of
serotoninergic hyperfunction, because of the inhibitory
effect of serotonin on dopamine neurons. In relation to
Awaki et al.’s results, we could justify our results. In fact,
in this case, both cabergoline treatment and lower PRL
can explain migraine improvement.
Different headache types may be triggered by pro-
lactinomas, but in cases of microprolactinomas, tumour
size and dural stretch are unlikely to cause headache
[17]. Treatment with dopamine agonist can determine
various responses [25]. Dopamine antagonists have been
used successfully in acute migraine treatment [26], and
there is evidence that alterations in dopamine may occur
during migraine attacks [27]. Alteration of headache phe-
notypes after administration of dopamine agonists sug-
gests that headache syndromes associated with prolactin-
omas may be the result of alterations in the dopamine-
prolactin axis rather than simply caused by the mass
effects of the tumour, also because the headache begins
months before hormonal symptoms for pituitary disor-
ders appear [17, 25]. The theory, stating that neuroen-
docrine mechanisms can be an important factor in trig-
gering and aborting headache, is supported by the result
of studies regarding the analgesic effect of somatostatin
analogues [28–31]. Our seven cases seem to support the
theory that high PRL levels alone are implicated in mak-
ing the headache chronic. The headache type, in fact, did
not change in the patients that we studied, it just wors-
ened, but subsequently improved after taking cabergoline
for a few months. The seventh patient is the only excep-
tion. Her headache improved in spite of PRL growth. In
this patient the factor that could have caused her
headache to worsen was probably estroprogestinics; this
therapy also stimulates PRL secretion [32]. In this case
we cannot really suspect pituitary dysfunction, but only
pituitary stimulation due to an estrogenic influence.
Another hypothesis that can be mentioned is to consider
headache in these patients as a possible secondary
headache due to hyperprolactinaemia in predisposed sub-
jects, such as migraineurs. What seems strange is that
headache maintains the typical characteristics of
migraine, and in patients 5 and 6, after improving, it no
longer seems to be migraine, but instead tension-type
headache. We can propose that what is already suggested
for other types of headache by other authors can also be
applicable to migraineurs, and that serotoninergic
dopaminergic systems, and perhaps other hypothalamic
hypophysial mechanisms, are important in determining
migraine expression. It is difficult to understand the
whole system completely because of the wide presence
and interaction between all of the transmitters and hor-
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mones. Furthermore, it is probably incorrect to state that
one rather than another of these systems is or is not
implicated in migraine physiopathology.
When dealing with a patient and when considering the
worsening of a primary headache, it is important to eval-
uate different co-factors even if headache maintains the
same characteristics. Considering previous reported cases
as well as ours, PRL levels should always be considered
as a cause of worsening, even if menstrual alteration or
galactorrhoea are not present and MRI is normal. In fact,
if confirmed, it is a possible adjunctive worsening factor,
which can be easily eliminated.
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